E
XTL Biopharmaceuticals Ltd. XTLB
$0.8038 -$0.0557-6.48%
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
52-Week Range
P/E (TTM)
--
EPS (TTM)
E
Sell 8/29/2023Downgrade
XTL Biopharmaceuticals Ltd. (XTLB) was downgraded to E+ from D- on 8/29/2023 due to a decline in the volatility index and total return index.
D
Sell 8/14/2023Upgraded
XTL Biopharmaceuticals Ltd. (XTLB) was upgraded to D- from E+ on 8/14/2023 due to an increase in the volatility index.
E
Sell 7/27/2023Downgrade
XTL Biopharmaceuticals Ltd. (XTLB) was downgraded to E+ from D- on 7/27/2023 due to a decline in the total return index and volatility index.
D
Sell 4/10/2023Downgrade
XTL Biopharmaceuticals Ltd. (XTLB) was downgraded to D- from D on 4/10/2023 due to a major decline in the efficiency index, growth index and solvency index. Earnings per share declined from -$0.0005 to -$0.0014, net income declined 162.46% from -$285 to -$748, and the quick ratio declined from 29.98 to 19.9.
D
Sell 12/12/2022Upgraded
XTL Biopharmaceuticals Ltd. (XTLB) was upgraded to D from D- on 12/12/2022 due to an increase in the efficiency index.
D
Sell 11/25/2022Downgrade
XTL Biopharmaceuticals Ltd. (XTLB) was downgraded to D- from D on 11/25/2022 due to a decline in the volatility index and total return index.
D
Sell 11/8/2022Upgraded
XTL Biopharmaceuticals Ltd. (XTLB) was upgraded to D from D- on 11/8/2022 due to an increase in the volatility index.
D
Sell 10/21/2022Downgrade
XTL Biopharmaceuticals Ltd. (XTLB) was downgraded to D- from D on 10/21/2022 due to a decline in the volatility index and total return index.
D
Sell 10/4/2022Upgraded
XTL Biopharmaceuticals Ltd. (XTLB) was upgraded to D from D- on 10/4/2022 due to an increase in the volatility index and total return index.
D
Sell 9/15/2022Downgrade
XTL Biopharmaceuticals Ltd. (XTLB) was downgraded to D- from D on 9/15/2022 due to a significant decline in the total return index, volatility index and growth index. Earnings per share declined from $0.0024 to -$0.0005.
D
Sell 11/9/2021Upgraded
XTL Biopharmaceuticals Ltd. (XTLB) was upgraded to D from E+ on 11/09/2021.
E
Sell 11/8/2021Downgrade
XTL Biopharmaceuticals Ltd. (XTLB) was downgraded to E+ from D on 11/8/2021 due to a major decline in the efficiency index, total return index and solvency index. Total capital declined 9.14% from $3.61M to $3.28M.
D
Sell 3/12/2021Downgrade
XTL Biopharmaceuticals Ltd. (XTLB) was downgraded to D from D+ on 3/12/2021 due to a decline in the total return index.
D
Sell 2/24/2021Upgraded
XTL Biopharmaceuticals Ltd. (XTLB) was upgraded to D+ from D on 2/24/2021 due to a significant increase in the total return index and volatility index.
D
Sell 9/10/2019Upgraded
XTL Biopharmaceuticals Ltd. (XTLB) was upgraded to D from D- on 9/10/2019 due to a large increase in the total return index, growth index and volatility index. Earnings per share increased from $0.0001 to $0.002.
D
Sell 3/16/2018Upgraded
XTL Biopharmaceuticals Ltd. (XTLB) was upgraded to D- from E+ on 3/16/2018 due to a major increase in the efficiency index, volatility index and solvency index.
E
Sell 11/1/2016Downgrade
XTL Biopharmaceuticals Ltd. (XTLB) was downgraded to E+ from D- on 11/1/2016 due to a decline in the volatility index and total return index.
D
Sell 9/30/2016Upgraded
XTL Biopharmaceuticals Ltd. (XTLB) was upgraded to D- from E+ on 9/30/2016 due to a noticeable increase in the growth index, volatility index and valuation index. Earnings per share increased from -$0.146 to -$0.04, and EBIT increased 37.37% from -$744 to -$466.
E
Sell 4/1/2016Downgrade
XTL Biopharmaceuticals Ltd. (XTLB) was downgraded to E+ from D- on 4/1/2016 due to a large decline in the growth index, efficiency index and valuation index. Net income declined 433.86% from -$443 to -$2.37M, earnings per share declined from -$0.04 to -$0.146, and EBIT declined 87.88% from -$396 to -$744.
D
Sell 3/11/2016Downgrade
XTL Biopharmaceuticals Ltd. (XTLB) was downgraded to D- from D+ on 3/11/2016 due to a substantial decline in the volatility index, total return index and efficiency index. Total capital declined 5.33% from $7.63M to $7.22M, and net income declined 3.75% from -$427 to -$443.
D
Sell 12/28/2015Upgraded
XTL Biopharmaceuticals Ltd. (XTLB) was upgraded to D+ from D on 12/28/2015 due to an increase in the valuation index and total return index.
D
Sell 3/10/2014Downgrade
XTL Biopharmaceuticals Ltd. (XTLB) was downgraded to D from D+ on 3/10/2014 due to a substantial decline in the volatility index and total return index.
Weiss Ratings